CSL Behring‘s HEMOPEXIN FIRST IN HUMAN
STUDY IN STABLE SICKLE DISEASE
Study Title:
A Phase 1, Multi-Center, Open Label, Single Ascending
Dose Study to Evaluate the Safety, Tolerability, and
Pharmacokinetics of CSL889 in Adult Patients with
Stable Sickle Cell Disease
ClinicalTrial.gov: NCT04285827